Welcome to our dedicated page for Scinai Immunotherapeutics Ltd. news (Ticker: SCNI), a resource for investors and traders seeking the latest updates and insights on Scinai Immunotherapeutics Ltd. stock.
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) is a biopharmaceutical company that regularly publishes updates on its dual business model: development of inflammation and immunology (I&I) biologics and operation of a boutique biologics CDMO under the Scinai Bioservices brand. The news flow around SCNI reflects both scientific progress and the evolution of its contract development and manufacturing activities.
Company press releases highlight several recurring themes. On the R&D side, Scinai reports advances in its NanoAb-based I&I pipeline, including anti‑IL‑17 programs for psoriasis and additional NanoAbs arising from collaborations with the Max Planck Society and University Medical Center Göttingen. News items also cover the PC111 program, a first‑in‑class human anti-Fas Ligand monoclonal antibody being developed for severe dermatological conditions such as pemphigus vulgaris and SJS/TEN through an option agreement to acquire Pincell Srl.
On the CDMO side, Scinai’s news frequently addresses growth in Scinai Bioservices, including revenue contributions from its U.S. subsidiary, new service orders, and infrastructure expansions such as an Israel Innovation Authority grant to fund an advanced sterile fill‑and‑finish system. These updates provide context on how the company is expanding its role as a boutique CDMO serving early-stage biotech clients in Israel, the United States, and Europe.
Investors and industry observers can also find announcements on equity financing arrangements, grant applications and outcomes, participation in sector conferences, and governance or cost-structure changes reported via Form 6‑K. This news page aggregates those releases so readers can follow SCNI’s financial results, pipeline milestones, CDMO capacity developments, and strategic transactions over time.
Scinai (NASDAQ: SCNI) completed a strategic reorganization on April 6, 2026, creating a dedicated CDMO subsidiary, Scinai Biopharma Services, following its February 2026 acquisition of Recipharm Israel (Yavne site). The move separates CDMO operations from a leaner R&D-focused Scinai Immunotherapeutics and targets ~$5 million in CDMO revenues for 2026.
The CDMO platform combines Jerusalem biologics capabilities, Yavne small-molecule/API capacity, and a commercial collaboration with Recipharm that provides subcontracting access and referral-based royalties.
Scinai (NASDAQ: SCNI) reported full-year 2025 results with CDMO revenues doubling to $1.3 million and a year-end cash position of $1.8 million. Net loss was $8.3 million, driven in part by the absence of 2024 financial income. Post‑year-end, Scinai acquired Recipharm Israel and signed a strategic collaboration to expand CDMO capabilities into small‑molecule manufacturing. The company resubmitted a FENG grant request that could provide up to €12 million in funding matched by ~€3 million company investment.
Scinai Immunotherapeutics (Nasdaq: SCNI) will attend BIO-Europe Spring 2026 in Lisbon March 23–25, showcasing its expanded CDMO platform and antibody-based immunology pipeline following the acquisition of Recipharm Israel and a strategic collaboration with Recipharm.
Highlights: integrated cGMP biologics site in Jerusalem, acquired cGMP small-molecule API site in Yavne, a client "graduation" model from early development to commercial supply, and a dermatology-focused antibody pipeline licensed from Max Planck, University Medical Center Göttingen, and PinCell.
Scinai Immunotherapeutics (Nasdaq: SCNI) said it received a Nasdaq written notice dated March 12, 2026, for noncompliance with the Nasdaq Capital Market minimum $1.00 bid price rule after ADSs closed below $1.00 for 30 consecutive business days.
The notice does not affect current listing or trading and provides an initial 180-calendar-day compliance period through September 8, 2026 to regain the $1.00 minimum by achieving at least ten consecutive business days at or above $1.00. The company said it will monitor the ADS closing price and evaluate options to regain compliance.
Scinai (Nasdaq: SCNI) executed a Second Amendment to its PinCell option agreement and submitted a revised €12 million non-dilutive FENG SMART Path application to support a €15 million integrated R&D program for PC111, a fully human anti-sFasL antibody for PV and SJS/TEN.
The amendment extends option condition deadlines to August 31, 2026 and the exercise period to September 30, 2026. A funding decision is expected in approximately three to four months.
Scinai (Nasdaq: SCNI) secured expanded Israel Innovation Authority support for its robotic aseptic fill & finish program, enabling use of the full approved grant of NIS 5 million over two years, ~66% non-dilutive. Validation is targeted for completion in Q3 2026.
The investment supports acquisition and validation of a robotic-arm system aligned with EU GMP Annex 1 and complements Scinai's recent Recipharm Israel acquisition and strategic commercial collaboration to create an integrated two-site CDMO platform.
Scinai (NASDAQ: SCNI) completed the acquisition of 100% of Recipharm Israel Ltd., adding a cGMP Yavne manufacturing site and expanding Scinai's CDMO footprint and technical scope.
The companies also signed a long-term commercial collaboration granting Scinai preferred early-stage status and access to Recipharm's global manufacturing network under predefined terms, plus a Master Quality Agreement and Tech Transfer Framework to streamline program transitions.
Scinai (Nasdaq: SCNI) announced that CEO Amir Reichman will co-lead a Manufacturers Association roundtable titled "Biopharma Manufacturing in Israel: Capabilities, Gaps, and Scale" on January 19, 2026 at Expo Tel Aviv during HealthIL Week 2026.
The session will focus on early-stage development, CMC and analytical capabilities, clinical GMP manufacturing, access to laboratory infrastructure, and readiness for later-stage and commercial manufacturing in Israel.
Participants will include government agencies, local and international biopharma companies, CDMOs, multinationals, and investors; the discussion aims to identify structural gaps and collaboration models to strengthen Israel's biopharma manufacturing ecosystem over the next 5–10 years.
Scinai (NASDAQ: SCNI) reported nine-month 2025 results and corporate updates. Revenues were $1,049k vs $452k a year earlier, driven by CDMO expansion including $502k from its U.S. subsidiary. R&D expenses fell to $1,799k from $4,195k; MG&A were $1,929k. Financial expenses, net were $607k versus financial income of $13,374k in 2024. Net loss was $6,244k versus net profit $7,026k year-ago. Cash and short-term deposits totaled $3,005k.
Operational highlights: a NIS 809k (~$246k) non-dilutive IIA grant for sterile fill-finish (installation Q1 2026, commercial Q2 2026); two separate €15m STEP grant decisions expected Q1 2026 for NanoAb programs; PC111 €12m FENG grant was not approved and Scinai is re-evaluating options, with a Pincell SPA option conditional on demonstrating $3m earmarked by Feb 28, 2026.
Scinai (NASDAQ: SCNI) received a non-dilutive Israel Innovation Authority grant of NIS 809,000 (~$246,000), funding ~66% of a NIS 1.23 million (~$373,000) project to acquire and install an advanced small-batch sterile fill-and-finish system.
Installation and qualification are expected in Q1 2026 with commercial operation planned in Q2 2026. The upgrade aims to expand Scinai Bioservices' GMP fill-and-finish capacity, enable rapid batch turnaround across primary packaging formats, and support clients in Israel, the U.S., and Europe while meeting EMA and FDA cGMP standards.
Scinai also continues R&D programs and holds an option to acquire PinCell Srl (PC111) and retains licensing options for NanoAbs from MPG and UMG.